Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
Holding ACRV?
Track your performance easily
ACRV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.19 - $11.90
Previous Close$6.23
Volume26.62K
Average Volume (3M)62.10K
Market Cap
$193.98M
Enterprise Value$10.54M
Total Cash (Recent Filing)$187.45M
Total Debt (Recent Filing)$4.01M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 26, 2025EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding31,136,296
10 Day Avg. Volume68,971
30 Day Avg. Volume62,096
Standard Deviation0.26
R-Squared0.00678
Alpha0.00219
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.99
Price to Sales (P/S)1447.61
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit78.65
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$21.67Price Target Upside250.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Acrivon Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing registrational-intent study for ACR-368 has shown a 62.5% overall response rate in OncoSignature positive patients with endometrial cancer, highlighting its effectiveness.
Financial PositionAcrivon has a strong cash position with $202.8 million on the balance sheet, which is expected to support its operations until the second half of 2026, ensuring financial stability.
Research And DevelopmentThe dual WEE1/PKMYT1 inhibitor, ACR-2316, has demonstrated significant anti-tumor activity in preclinical models and has dosed its first patient ahead of schedule in a Phase 1 trial, marking a promising advancement in the pipeline.
Bears Say
Clinical Trial DesignThe need for anemia management in trials of similar PKMYT1 targets highlights potential challenges for Acrivon in their own Phase 1 trial design.
Drug Class EfficacyData from a peer's trial with a similar WEE1 inhibitor showed no objective responses, highlighting challenges in this drug class.
Drug Development ChallengesThe program was in-licensed from Lilly following a failure to meet target efficacy levels of 30%-40%.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $3.19 and its highest was $11.90 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 89 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.578 by -$0.012.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -$0.66.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,136,295 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.578. Following the earnings report the stock price went down -5.483%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Among the largest hedge funds holding Acrivon Therapeutics, Inc.’s share is RA Capital Management. It holds Acrivon Therapeutics, Inc.’s shares valued at 58M.
---
Acrivon Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.67 (250.08% Upside)
$21.67 (250.08% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.84%
12-Months-Change
Fundamentals
Return on Equity
-45.95%
Trailing 12-Months
Asset Growth
42.09%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Month Forecast
Average Price Target
$21.67
▲(250.08% Upside)
Technical Analysis
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-5.08%
reiterated a buy rating last month
Copying Etzer Darout's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -5.08% per trade.
---